Lilly posts Q3 2026 revenue of $24.4B, raises full-year 2026 guidance
Lilly reported Q3 2026 revenue of $24.4 billion, a 39% increase, driven by Mounjaro and Zepbound, and raised its full-year 2026 revenue guidance to $91.0 to $92.0 billion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed